NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma

Overview

Journal PLoS Med

Specialty General Medicine

Date 2007 Mar 1

PMID 17326708

Citations 125

Authors

Patricia C Galipeau

Xiaohong Li

Patricia L Blount

Carlo C Maley

Carissa A Sanchez

Robert D Odze

Kamran Ayub

Peter S Rabinovitch

Thomas L Vaughan

Brian J Reid

Affiliations

Soon will be listed here.

Abstract

Background: Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may modulate progression. We aimed to evaluate somatic genetic abnormalities with NSAIDs as predictors of EA in a prospective cohort study of patients with BE.

Methods And Findings: Esophageal biopsies from 243 patients with BE were evaluated at baseline for TP53 and CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing; loss of heterozygosity (LOH); methylation-specific PCR; and flow cytometry. At 10 y, all abnormalities, except CDKN2A mutation and methylation, contributed to EA risk significantly by univariate analysis, ranging from 17p LOH (relative risk [RR] = 10.6; 95% confidence interval [CI] 5.2-21.3, p < 0.001) to 9p LOH (RR = 2.6; 95% CI 1.1-6.0, p = 0.03). A panel of abnormalities including 17p LOH, DNA content tetraploidy and aneuploidy, and 9p LOH was the best predictor of EA (RR = 38.7; 95% CI 10.8-138.5, p < 0.001). Patients with no baseline abnormality had a 12% 10-y cumulative EA incidence, whereas patients with 17p LOH, DNA content abnormalities, and 9p LOH had at least a 79.1% 10-y EA incidence. In patients with zero, one, two, or three baseline panel abnormalities, there was a significant trend toward EA risk reduction among NSAID users compared to nonusers (p = 0.01). The strongest protective effect was seen in participants with multiple genetic abnormalities, with NSAID nonusers having an observed 10-y EA risk of 79%, compared to 30% for NSAID users (p < 0.001).

Conclusions: A combination of 17p LOH, 9p LOH, and DNA content abnormalities provided better EA risk prediction than any single TP53, CDKN2A, or DNA content lesion alone. NSAIDs are associated with reduced EA risk, especially in patients with multiple high-risk molecular abnormalities.

Citing Articles

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.

Ganguli P, Basanta C, Acha-Sagredo A, Misetic H, Armero M, Mendez A Nat Cancer. 2025; 6(1):158-174.

PMID: 39753721 PMC: 11779637. DOI: 10.1038/s43018-024-00876-0.

Single nucleus DNA sequencing of flow sorted archived frozen and formalin fixed paraffin embedded solid tumors.

Zhou Y, Chen X, Chapman J, Barrett M BMC Genomics. 2024; 25(1):943.

PMID: 39379794 PMC: 11460195. DOI: 10.1186/s12864-024-10850-w.

Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.

Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).

PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.

Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.

Ergun P, Kipcak S, Bor S Int J Mol Sci. 2023; 24(9).

PMID: 37175524 PMC: 10178512. DOI: 10.3390/ijms24097817.

Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.

Uno K, Koike T, Hatta W, Saito M, Tanabe M, Masamune A Diagnostics (Basel). 2022; 12(10).

PMID: 36292126 PMC: 9600913. DOI: 10.3390/diagnostics12102437.

References

Lindblad M, Garcia Rodriguez L, Lagergren J . Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control. 2005; 16(3):285-94. DOI: 10.1007/s10552-004-3485-7. View

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y . Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene. 2005; 24(25):4138-48. DOI: 10.1038/sj.onc.1208598. View

Cook N, Lee I, Gaziano J, Gordon D, Ridker P, Manson J . Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294(1):47-55. DOI: 10.1001/jama.294.1.47. View

Reid B, Prevo L, Galipeau P, Sanchez C, Longton G, Levine D . Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001; 96(10):2839-48. PMC: 1808263. DOI: 10.1111/j.1572-0241.2001.04236.x. View

Engel L, Chow W, Vaughan T, Gammon M, Risch H, Stanford J . Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95(18):1404-13. DOI: 10.1093/jnci/djg047. View

Conio M, Blanchi S, Lapertosa G, Ferraris R, Sablich R, Marchi S . Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol. 2003; 98(9):1931-9. DOI: 10.1111/j.1572-0241.2003.07666.x. View

King M, Marks J, Mandell J . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645):643-6. DOI: 10.1126/science.1088759. View

Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo M, Sugihara K . A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res. 2003; 9(13):4756-60. View

Sherr C . Principles of tumor suppression. Cell. 2004; 116(2):235-46. DOI: 10.1016/s0092-8674(03)01075-4. View

10.

McManus D, Olaru A, Meltzer S . Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. 2004; 64(5):1561-9. DOI: 10.1158/0008-5472.can-03-2438. View

11.

Fahmy M, Skacel M, Gramlich T, Brainard J, Rice T, Goldblum J . Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004; 17(5):588-96. DOI: 10.1038/modpathol.3800088. View

12.

Gonzalez-Perez A, Garcia Rodriguez L, Lopez-Ridaura R . Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer. 2003; 3:28. PMC: 272929. DOI: 10.1186/1471-2407-3-28. View

13.

Maley C, Galipeau P, Li X, Sanchez C, Paulson T, Reid B . Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 2004; 64(10):3414-27. DOI: 10.1158/0008-5472.CAN-03-3249. View

14.

Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G . Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer. 2004; 110(6):850-6. DOI: 10.1002/ijc.20180. View

15.

Paulson T, Reid B . Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell. 2004; 6(1):11-6. DOI: 10.1016/j.ccr.2004.06.021. View

16.

Maley C, Galipeau P, Li X, Sanchez C, Paulson T, Blount P . The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 2004; 64(20):7629-33. DOI: 10.1158/0008-5472.CAN-04-1738. View

17.

Fennerty M, Sampliner R, Way D, Riddell R, Steinbronn K, Garewal H . Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology. 1989; 97(4):815-20. DOI: 10.1016/0016-5085(89)91483-2. View

18.

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

19.

Meltzer S, Yin J, Huang Y, McDaniel T, Newkirk C, Iseri O . Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1991; 88(11):4976-80. PMC: 51790. DOI: 10.1073/pnas.88.11.4976. View

20.

Cameron A, Lomboy C . Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992; 103(4):1241-5. DOI: 10.1016/0016-5085(92)91510-b. View